Leukemia
In this section, we cover the latest in cutting-edge leukemia news and research. Leukemias are a group of diseases that result from the unregulated clonal proliferation of cells secondary to genetic abnormalities in hematopoietic cells. Compared to normal cells, a high rate of proliferation and low rate of apoptosis offers leukemic cells a growth advantage.
Advertisement
Acute Lymphoblastic Leukemia
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
The awards recognize early-, mid-, or senior-career experts who display excellence in the field.
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Acute Myeloid Leukemia
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Sankalp Arora, MBBS, a second-year fellow at MD Anderson, presented data on FLT3 inhibitors in AML at the HemOnc Pulse Live.
Results from the phase 1b study suggest venetoclax plus modified chemotherapy is an effective and well-tolerated approach.
Tuspetinib in combination with venetoclax and azacitidine showed promising clinical safety and antileukemic activity in AML.
Presented preclinical model data show significant efficacy against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Chronic Lymphocytic Leukemia
A short duration of covalent BTKi therapy and early disease progression were associated with low incidence of BTK mutations.
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Dr. Rogers shares her career trajectory, what being a doctor is about, and a glimpse of her pet guinea pigs, Maple and Brady.
CLL treatment is evolving. Dr. Ryan Jacobs shares why decisions now weigh indefinite therapy vs. time-defined options.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Chronic Myeloid Leukemia
Experts debate frontline CLL therapy—time-limited combos vs long-term BTKi—and the role of MRD in treatment decisions.
ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Ryan Jacobs, MD discusses 2025 CLL treatment advances, including BTK/BCL-2 combos, resistance, and time-defined strategies.
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.